Back to All Events

Fireside Chat: Collaborating to Lay the Groundwork for Molecular Residual Disease as an Early Endpoint in Solid Tumors

  • Next Generation Dx Conference Washington, DC (map)

In this session at the Next Generation Dx 2023 Conference, BLOODPAC’s Executive Director will lead a discussion on the following topics:

  • How BLOODPAC works collaboratively to develop and execute a strategic plan for MRD implementation

  • BLOODPAC's progress in establishing an MRD lexicon, determining recommended data elements, and developing clinical protocols 

  • The value of data curation and a data commons in accelerating research

  • Next steps in moving towards clinical use of MRD

Panelists include Gregory Jones (Head of Precision Diagnostics, NeoGenomics) and Christina Lockwood (Associate Professor, University of Washington; Director, Genetics & Solid Tumors Laboratory; Medical Director, Brotman Baty Institute for Precision Medicine).

Source: https://www.nextgenerationdx.com/liquid-biopsy
Previous
June 27

Molecular Residual Disease Testing: Confidence and Consistency in MRD assays
Next
August 22

Creating Consensus on a Lexicon, Standards, and Frameworks for Multi-Cancer Detection (Talk)